Thyroid function in heart failure and impact on mortality.

OBJECTIVES The aim of this study was to investigate whether patients with systolic heart failure (HF) and abnormal thyroid function are at increased risk for death. BACKGROUND Thyroid hormone homeostasis is vital to the optimal functioning of the cardiovascular system, but an independent prognostic effect of thyroid abnormalities in patients with HF has not been established. METHODS In SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial), which randomized patients with ischemic or nonischemic HF to placebo or amiodarone or implantable cardioverter-defibrillator therapy, thyroid-stimulating hormone (TSH) was measured at baseline and at 6-month intervals throughout the 5-year study. RESULTS Of 2,225 patients, the majority (87%) had normal TSH levels (0.3 to 5.0 μU/ml) at baseline, 12% had values suggestive of hypothyroidism, and 1% had values consistent with hyperthyroidism. Compared with euthyroid patients, those hypothyroid at baseline were older and included more women and Caucasians (all p values <0.05). Over the median follow-up period of 45.5 months, among patients euthyroid at baseline, 89 developed abnormally low TSH levels, and 341 developed abnormally high values. Patients randomized to amiodarone (median dose 300 mg) had an elevated risk for developing abnormal TSH levels compared with implantable cardioverter-defibrillator therapy or placebo (p < 0.0001). Patients with baseline or new-onset abnormal thyroid function had a higher mortality than those with normal thyroid function, even after controlling for other known mortality predictors (hazard ratio: 1.58; 95% confidence interval: 1.29 to 1.94; p < 0.0001 for hypothyroid; hazard ratio: 1.85; 95% confidence interval: 1.21 to 2.83; p = 0.0048 for hyperthyroid). Implantable cardioverter-defibrillator benefit did not vary with thyroid function. CONCLUSIONS Abnormal thyroid function in patients with symptomatic HF and ejection fractions ≤35% is associated with significantly increased risk for death, even after controlling for known mortality predictors.

[1]  D. Bauer,et al.  Thyroid Studies Collaboration , 2010 .

[2]  N. Goldschlager,et al.  Practical guidelines for clinicians who treat patients with amiodarone. Practice Guidelines Subcommittee, North American Society of Pacing and Electrophysiology. , 2000, Archives of internal medicine.

[3]  I. Klein,et al.  Thyroid disease and the heart. , 2007, Circulation.

[4]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2010 update: a report from the American Heart Association. , 2010, Circulation.

[5]  William T. Abraham,et al.  Focused Update : ACCF / AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults , 2013 .

[6]  A. Hofman,et al.  High-normal thyroid function and risk of atrial fibrillation: the Rotterdam study. , 2008, Archives of internal medicine.

[7]  E. Mazzaferri.  Thyroid Status, Cardiovascular Risk, and Mortality in Older Adults , 2007 .

[8]  Douglas L Packer,et al.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. , 2005, The New England journal of medicine.

[9]  D.,et al.  Regression Models and Life-Tables , 2022 .

[10]  E. Vittinghoff,et al.  Subclinical Thyroid Dysfunction and the Risk of Heart Failure Events: An Individual Participant Data Analysis From 6 Prospective Cohorts , 2012, Circulation.

[11]  E. Vittinghoff,et al.  Subclinical hypothyroidism and the risk of heart failure, other cardiovascular events, and death. , 2005, Archives of internal medicine.

[12]  J. H. Patterson,et al.  Executive Summary Executive Summary : HFSA 2010 Comprehensive Heart Failure Practice Guideline , 2022 .

[13]  Peter O'Leary,et al.  Subclinical thyroid dysfunction as a risk factor for cardiovascular disease. , 2005, Archives of internal medicine.

[14]  J. Ornato,et al.  ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article , 2005 .

[15]  F. Tseng,et al.  Subclinical hypothyroidism is associated with increased risk for all-cause and cardiovascular mortality in adults. , 2012, Journal of the American College of Cardiology.

[16]  A. L'Abbate,et al.  Low-T3 Syndrome: A Strong Prognostic Predictor of Death in Patients With Heart Disease , 2003, Circulation.

[17]  S. Pearce,et al.  Levothyroxine treatment of subclinical hypothyroidism, fatal and nonfatal cardiovascular events, and mortality. , 2012, Archives of internal medicine.

[18]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[19]  D. Mozaffarian,et al.  Executive summary: heart disease and stroke statistics--2010 update: a report from the American Heart Association. , 2010, Circulation.

[20]  G. Canaris,et al.  The Colorado thyroid disease prevalence study. , 2000, Archives of internal medicine.

[21]  M. Helfand.  Screening for Subclinical Thyroid Dysfunction in Nonpregnant Adults: A Summary of the Evidence for the U.S. Preventive Services Task Force , 2004, Annals of Internal Medicine.

[22]  E. Vittinghoff,et al.  Subclinical thyroid dysfunction, cardiac function, and the risk of heart failure. The Cardiovascular Health study. , 2008, Journal of the American College of Cardiology.